Anti-PI 3 Kinase p110 delta 抗体 [Y387] (ab32401)

ab32401 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab32401 は 6 報の論文で使用されています。

  • Conte E  et al. PI3K p110? overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest 93:566-76 (2013). WB ; Human . PubMed: 23439433
  • Law AJ  et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110d inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A 109:12165-70 (2012). PubMed: 22689948
  • Suárez-Fueyo A  et al. Enhanced phosphoinositide 3-kinase d activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 187:2376-85 (2011). IP . PubMed: 21810603
  • Jiang X  et al. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 285:14980-9 (2010). WB ; Human . PubMed: 20231295
  • Pang H  et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 69:8868-76 (2009). PubMed: 19903845
  • Jaiswal BS  et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16:463-74 (2009). PubMed: 19962665

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"